Extra £14m pushes STORM Series A funding to £30m | Business Weekly | Technology News | Business news | Cambridge and the East of England
Summary
STORM is a University of Cambridge spin-out translating the ground-breaking work of Professors Tony Kouzarides and Eric Miska in RNA epigenetics into the discovery of first-in-class drugs in oncology and other diseases. Dr Albertella was previously Director of Biology at Medivir AB and has a successful track record in oncology drug discovery and development at Argenta, OSI Pharmaceuticals, Kudos and AstraZeneca. “This investment strengthens our Series A and provides further validation and support for STORMs strategy to continue building a world-leading company harnessing the power of RNA epigenetics - an emerging, innovative area of drug discovery. We believe STORM is maintaining its first-mover advantage in RNA epigenetic modulation and is progressing rapidly in its development, making this an exciting time for us to partner with management and co-investors. “We continue to be impressed by the quality and depth of STORMs science and the significant progress made by the team to advance its platform and pipeline in this fast-moving area of emerging biology.